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Abstract
Background: Antibiotic associated diarrhea and Clostridium difficile infection are frequent complications of broad
spectrum antibiotic therapy. Probiotic bacteria are used as therapeutic and preventive agents in these disorders,
but the exact functional mechanisms and the mode of action are poorly understood. The effects of clindamycin
and the probiotic mixture VSL#3 (containing the 8 bacterial strains Streptococcus thermophilus, Bifidobacterium breve,
Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus
paracasei and Lactobacillus delbrueckii subsp. Bulgaricus) consecutively or in combination were investigated and
compared to controls without therapy using a standardized human fecal microbiota in a computer-controlled in
vitro model of large intestine. Microbial metabolites (short chain fatty acids, lactate, branched chain fatty acids, and
ammonia) and the intestinal microbiota were analyzed.
Results: Compared to controls and combination therapy, short chain fatty acids and lactate, but also ammonia and
branched chain fatty acids, were increased under probiotic therapy. The metabolic pattern under combined
therapy with antibiotics and probiotics had the most beneficial and consistent effect on intestinal metabolic
profiles. The intestinal microbiota showed a decrease in several indigenous bacterial groups under antibiotic
therapy, there was no significant recovery of these groups when the antibiotic therapy was followed by
administration of probiotics. Simultaneous application of anti- and probiotics had a stabilizing effect on the
intestinal microbiota with increased bifidobacteria and lactobacilli.
Conclusions: Administration of VSL#3 parallel with the clindamycin therapy had a beneficial and stabilizing effect
on the intestinal metabolic homeostasis by decreasing toxic metabolites and protecting the endogenic microbiota
from destruction. Probiotics could be a reasonable strategy in prevention of antibiotic associated disturbances of
the intestinal homeostasis and disorders.
Background
Antibiotic-associated diarrhea (AAD) and Clostridium
difficile infection (CDI) are frequent complications of
broad-spectrum antibiotic therapy. In a large prospective
multicenter study, AAD was observed in 4.9% of the
patients (1.8%-6.9%) receiving long-term antibiotic treat-
ment with > 50% of patients showing positive testing for
C. difficile toxin B [1]. The incidence of CDI is still
increasing [2,3] and the disease is complicated by the
occurrence of virulent and pathogenic C. difficile ribo-
types associated with higher morbidity and mortality,
which are responsible for CDI outbreaks worldwide [4].
The increasing incidence and mortality associated with
the CDI and the significant rate of treatment failures
and recurrences with current antibiotics emphasize the
role of preventative strategies.
Probiotics are promising agents in the prevention of
AAD and CDI. Originally they were used in the therapy
of AAD and CDI and for regeneration of intestinal
microbiota after antibiotic treatment. A significant
reduction of AAD and CDI could be observed in rando-
mized clinical trials when administered simultaneously
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with the antibiotic substances [5-8]. Probiotic microbes
have positive impact on microbe-microbe and host-
microbe interactions, and could also limit pathogen by
modulating gut microbiome competitive interactions
and/or by producing antimicrobial compounds [9-11].
Reports state positive effect of probiotics on beneficial
short chain fatty acid production and negative on harm-
ful net ammonia production [12,13].
However, the heterogeneity of probiotic formulations
and the vague definition of probiotics as otherwise not
classified microorganisms that improve health of the host
impede the assessment of clinical trials. Several effects
have been attributed to probiotics, among them direct
influences on the composition of intestinal microbiota,
the intestinal metabolism and the immune response
[14-16], but the exact mode of action is poorly under-
stood. Previously, we have developed a validated,
dynamic in vitro model of the gastrointestinal tract [17],
which allows for mode of action studies to be performed.
Mechanistic studies are difficult to perform in vivo due
to difficulties in sampling and ethical considerations. The
in vitro gastrointestinal model of the colon simulates to a
high degree the successive dynamic processes in the large
intestine [17]. The model is a unique tool to study the
stability, release, dissolution, absorption and bioconver-
sion of nutrients, chemicals, bioactive compounds and
pharmaceuticals in the gastrointestinal tract [18,19].
Besides the average physiological conditions and the bio-
logical variation, also abnormal or specific conditions can
be simulated in a reproducible way. The following stan-
dardized conditions are simulated: body temperature; pH
in the lumen; delivery of a pre-digested substrate from
the ‘ileum’; mixing and transport of the intestinal con-
tents; presence of a complex, high density, metabolically
active, anaerobic microbiota of human origin; and
absorption of water and metabolic products via a semi-
permeable membrane inside the colon model [17]. This
model has been validated successfully with regards to the
number and ratio of the various micro-organisms which
are similar in composition and metabolic activity with
that of the human colon. Furthermore, it has been vali-
dated for the production of metabolites, such as short-
chain fatty acids (SCFA), branched-chain fatty acids
(BCFA), gases, ammonia, and phenolic compounds and
used for studies on bioconversion of flavonoids [18] or
glucosinolates by the human colon microbiota [19].
The in vitro system can support scientific research, e.
g. studying the role of specific micro-organisms in the
fermentation of dietary fibers, the fate and function of
probiotics and other foods or drugs, and the develop-
ment of novel products in a shorter time.
In this study different therapeutic regimens (antibio-
tics; probiotics following antibiotics; antibiotics and pro-
biotics together; no therapy) were investigated in the
in vitro model using a standardized intestinal human
microbiota originating from healthy adult volunteers.
We monitored beneficial (SCFA and lactate) and putre-
factive/toxic (BCFA and ammonia) metabolites. The
intestinal microbiota composition was also analyzed
under the different conditions.
Methods
Test products
The two test products were Clindamycin and VSL #3.
Clindamycin (Fresenius Kabi, Bad Homburg, Germany) is
a broad-spectrum lincosamide antibiotic usually used to
treat anaerobic infections. It is effective against most
Gram-positive cocci and Gram-negative anaerobic bac-
teria and comparable with macrolide antibiotics. VSL#3
(Sigma-tau, Duesseldorf, Germany) is a multi-species
probiotic and contains the following 8 species: Strepto-
coccus thermophilus, Bifidobacterium breve, Bifidobacter-
ium longum, Bifidobacterium infantis, Lactobacillus
acidophilus, Lactobacillus plantarum, Lactobacillus
paracasei and Lactobacillus delbrueckii subsp. bulgaricus.
Ethical approval
A general ethical committee vote for the collection of
stool samples of healthy volunteers had been obtained
from the local ethical board of the Medical Faculty of the
Christian-Albrechts-University (CAU) in Kiel. All volun-
teers have given informed consent.
Test system: TNO large-intestinal model (TIM-2)
The study was performed in the TNO dynamic system
of the large intestine (TIM-2) as schematically repre-
sented in Figure 1 and as described in detail by Venema
et al. [20] and Minekus et al. [17].
Microbiota
The study was performed in TIM-2 with an active micro-
biota originating from ten healthy adults. Inclusion and
exclusion criteria were: age between 20 and 70 years, no
chronic or active disease, no medication (including any
antibiotic or pre/probiotic treatment at least 6 weeks
prior to enrolment in the study), no pregnancy, and no
stay at hospital within the last 6 months. The mean age
was 46.3 years, the gender ratio m:f was 5:5. Stool sam-
ples were collected and immediately snap-frozen in liquid
nitrogen at -196°C. The material was shipped on dry ice
to TNO. In order to increase the reproducibility of the
inoculation a standardized microbiota was prepared from
these stools according to Venema et al. [20].
Micro-ecological studies
After inoculation of the system with the microbiota the
experiments started with a 16 hour stabilization period
in which the microbiota could adapt to the system.
Thereafter the test period started. In the control unit
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the standard ileal efflux meal (SIEM) was fed to the sys-
tem. SIEM was given at a rate of 56 ml/day. Its compo-
sition is described in Maathuis et al. (2009). In brief, it
contained the following components: 2.5 g K2HPO4.3H2O,
4.5 g NaCl, 0.005 g FeSO4.7H2O, 0.5 g MgSO4.7H2O, 0.45
g CaCl2.2H2O, 0.4 g cysteine.HCl, 4.7 pectin, 4.7 xylan, 4.7
arabinogalactan, 4.7 amylopectin, 23.5 casein, 39.2 starch,
17 Tween 80, 23.5 bactopeptone, 0.4 bile, plus 1 ml of a
vitamin mixture containing (per litre): 1 mg menadione,
2 mg D-biotin, 0.5 mg vitamin B12, 10 mg pantothenate,
5 mg nicotinamide, 5 mg p-aminobenzoic acid and 4 mg
thiamine. The pH was kept constant at 5.8. The antibiotic
was administered as a shot at the start of the experiment
(1.5 mg) and furthermore the antibiotic was administered
with the SIEM (0.75 mg/day) and it was added to the dia-
lysate (10 mg/l) in order to prevent dialysis of antibiotic
out of the lumen. Dialysis liquid contained (per litre): 2.5 g
K2HPO4.3H2O, 4.5 g NaCl, 0.005 g FeSO4.7H2O, 0.5 g
MgSO4.7H2O, 0.45 g CaCl2.2H2O, 0.4 g cysteine.HCl, 0.05
bile, plus 1 ml of the vitamin mixture. The probiotic com-
pound was administered at a dose of 4.4 g per day con-
taining at least 450 billion bacteria (according to the
manufacturer), and was administered as a single shot each
24 h after dissolving the powder is 10 ml dialysis liquid.
In the TIM-2 experiments, the composition of the
colon microbiota was followed in time after intake of the
test compounds (Clindamycin and/or VSL#3) during sev-
eral days at a frequent intervals (see Figure 2 for setup of
the experiments). The control experiment without any
addition was performed as a single run, the variation
with the first 7 days addition of antibioics and then
7 days probiotics was performed in triplicate, while the
variation with the combined addition of probiotics +
antibiotics was performed in duplicate. Analysis of the
composition of the microbiota indicated the bacterial
genera which were selectively stimulated or suppressed
by the test compounds. In addition, samples were ana-
lyzed for SCFA, BCFA, lactate and ammonia. These
values provided an indication of the balance between
health-promoting and toxic products produced by the
microbiota after addition of the different compounds
i) separately and consecutively or ii) in combination.
Analysis of (changes in) these microbial metabolites pro-
vided information on the functionality of the changes
that took place in the microbiota.
Sampling
Before, during (every day at 24 h intervals) and at the end
of the fermentation experiments, samples were taken
from the lumen of the model and from the dialysis liquid
for analysis on metabolites. Each day 25 ml was taken out
of the system to simulate passage of stool. Additional
samples were taken from the lumen of the colon model
for analyzing the composition of the microbiota using the
I-Chip platform (description later in this material and
methods section). These samples were taken at day 0, day
7 and day 14.
Short chain fatty acids (SFCA) and branched chain fatty
acids (BCFA) analyses
The lumen and dialysis samples were analyzed gas-chro-
matographically on the concentrations of SCFA and
BCFA as follows: Samples were centrifuged (12000 rpm,
5 min) and a mixture of formic acid (20%), methanol and
2-ethyl butyric acid (internal standard, 2 mg/mL in
methanol) was added to the clear supernatant. According
Figure 1 Schematic representation of the TNO TIM-2 in vitro
model with (a) peristaltic compartments containing fecal
matter; (b) pH electrode; (c) alkali pump; (d) dialysis liquid
circuit with hollow fibre membrane; (e) level sensor; (f) N2 gas
inlet; (g) sampling port; (h) gas outlet; (i) ‘ileal efflux’ container
containing SIEM; (j) temperature sensor. In brief, the model
consists of four glass units with a flexible wall inside (peristaltic
compartments) and a total volume of 135 ml. Water of body
temperature (37°C) was pumped into the space between the glass
jacket and the flexible wall, causing the microbiota to be mixed and
moved. The sequential squeezing of the walls, controlled by a
computer, caused a peristaltic wave forcing the material to circulate
through the loop-shaped system. Physiological electrolyte and
metabolite concentrations in the lumen were maintained with a
dialysis system consisting of hollow fibres, running through the
lumen of the reactor, through which dialysis liquid was pumped at
a speed of 1.5 ml/min. The model further contained an inlet system
for delivery of the artificial ileal delivery medium (SIEM), and a level
sensor to maintain the luminal content at the set level of 135 ml.
The system was kept anaerobic by flushing with gaseous nitrogen.
At the start of each experiment the model was inoculated with 30
ml of the standard, cultivated faecal microbiota, consisting of a mix
of fecal samples from 7 individuals. The composition of this
microbiota consisted of all microbes present in the fecal donations
(unpublished data).
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to the method described by Jouany [21] as described in
detail by van Nuenen et al. [22], a 0.5-μL sample was
injected on a GC-column (Stabilwax-DA, length 15 m,
ID 0.53 mm, film thickness 0.1 mm; Varian Chrompack,
Bergen op Zoom, The Netherlands) in a Chrompack
CP9001 gas chromatograph using an automatic sampler
(Chrompack liquid sampler CP9050; Varian Chrompack).
Lactate
For lactate analysis the samples were centrifuged as
described above. In the clear supernatant both L- and
D-lactate were determined enzymatically (based on Boeh-
ringer, UV-method, Cat. No. 1112821) by a Cobas Mira
plus autoanalyzer (Roche, Almere, The Netherlands), as
described in detail by van Nuenen et al. [22]. The analysis
is based on the conversion of NAD + into NADH.
Ammonia
For the analysis for the protein-fermentative metabolite
ammonia samples were centrifuged as described above
and analyzed as described in detail by Van Nuenen
et al. [22]. The analysis is based on the conversion of
free ammonia with hypochlorite/phenol reagent into
blue indophenol. In the clear supernatant indophenol
was measured by measuring the absorbance at 600 nm
with a Cobas Mira Plus autoanalyzer.
I-Chip platform
The ‘intestinal chip’ (I-Chip) has been developed as a fas-
ter alternative method to determine the composition of
the microbiota. Sequences of approximately 400 microor-
ganisms have been placed on a DNA micro-array as pre-
viously described [23,24]. DNA was isolated from the
luminal samples of the TIM-2 experiments. Subsequently
the DNA was labeled and hybridized to DNA-arrays
printed with the probes. After washing the arrays were
scanned and analyzed. Analysis of the composition of the
microbiota (using I-chip) indicated the bacterial genera
which are selectively stimulated or suppressed by the anti-
biotic and/or probiotic. Changes in the composition of the
microbiota in the experiments in which Clindamycin was
applied for seven days, or in which Clindamycin plus pro-
biotics were applied together for seven days, were com-
pared with the changes in the control experiment in the
same time period. Changes in the composition of the
microbiota after application of probiotics sequentially after
the application of Clindamycin were compared to the
composition of the microbiota after the application of
Clindamycin for seven days.
SAM analysis
The data obtained with the I-chip were analyzed with
Significance Analysis of Microarrays (SAM) for statisti-
cal relevance [25].
Results and discussion
In vivo, Clindamycin shows good penetration into tissues
and is often used to treat skin or soft tissue infections.
Pseudomembranous colitis (PMC) caused by overgrowth
of Clostridium difficile is a potentially life-threatening
complication of antibiotic therapy. The probiotic product
VSL#3 is a dietary supplement often used for treatment
of various gastrointestinal complaints directly associated
with microbial dysbiosis such as chronic constipation,
diarrhea, flatulence, ulcerative colitis and pouchitis
[16,26,27].
The in vitro model used in this study provides stan-
dardized and reliable conditions to study the effects of
Division of sample Clindamycin + VSL#3(d 1-7)
Control (d 1-7)
Clindamycin + VSL#3(d 1-7) VSL#3 (d 8-14)
0   1   2   3   4    5    6   7   8  9  10  11  12  13  14
Sampling
+ + + 
*   *    *   *   *    *    *   *    *   *  *    *    *    *  * 
Pooled stool  
Sample of healthy 
individuls 
+ I chip analysis  (luminal content)
* Metabolic analysis (luminal content and dialysis fluid)
Figure 2 Schematic representation of study design and mode of sampling. A pooled stool sample was assigned to the three study arms
(Clindamycin for 7 days followed by VSL#3 for 7 days, Clindamycin + VSL#3 for 7 days, no therapy control for 7 days). Dialysis fluid and lumen
samples for metabolic analysis (SCFA, BCFA, lactate, ammonia) were collected daily, lumen samples for microbial analysis were sampled before
therapy and at the end of each 7 days period.
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pro- and antibiotics on the human intestinal microbiota
[17] and is has an advantage over living system in con-
tinuous sampling over a defined period of time. More-
over, the system is hardly biased by environmental
factors, e.g. temperature, humidity or oxygen, which can
be controlled to a high extent.
The TIM-2 experiments were performed using a stan-
dardized microbiota from healthy individuals. In the
control unit the standard ileal efflux meal (SIEM) was
fed to the system. In one experiment the antibiotic was
administered together with a probiotic mixture (VSL#3)
and in the other experiment the probiotic was adminis-
tered after the antibiotic treatment.
Production of beneficial microbial metabolites
Short chain fatty acids (SCFA) and lactate are beneficial
microbial metabolites. SCFA and lactate acidify the
intestinal lumen, causing growth arrest or even death of
(opportunistic pathogens). In addition, the SCFA are an
energy source for the host: butyrate for colonic epithelial
cells, acetate and propionate, in amongst others liver and
muscle cells [28-30]. Figure 3 presents cumulative total
production of the short chain fatty acids, e.g acetate, pro-
pionate and n-butyrate during the different experiments
in TIM-2, and represents metabolites present in lumen
and dialysate. The amount of SCFA present at the start
of the experiment has been artificially set to zero so the
graphs only reflect the production of metabolites after
start of addition of the test products.
The total SCFA production was not affected by the use
of Clindamycin or Clindamycin plus probiotics. When
probiotics were administered after the administration of
Clindamycin for one week, the SCFA production increased
since the slope of the total SCFA production increased in
the second week, compared with the first week of the
experiment. The production of n-butyrate and propionate
was increased when probiotics were added. The acetate
concentration was unaffected by the addition of Clindamy-
cin or probiotics. When Clindamycin and probiotics were
administered together the propionate production was
decreased. These differences are likely to be caused by
changes in the microbiota composition.
Figure 4 presents the cumulative total production of
lactate. Lactate was produced in all variations, but when
probiotics were added the lactate production was
increased, independent of the presence of Clindamycin.
The probiotics were lactic acid bacteria and the extra
production of lactate proved the probiotics were active in
the microbiota. Lactate is only accumulating when there
is a fast fermentation. If substrates are fermented slowly,
lactate is converted into the other SCFA (primarily pro-
pionate and butyrate) and does not accumulate.
The total SCFA production was not affected by the
use of antibiotics or antibiotics plus probiotics. When
Figure 3 Cumulative production of the short chain fatty acids (SCFA) acetate, propionate and n-butyrate during the different experiments
in TIM-2: (A) Clindamycin for 7 days (d 1-7 a) followed by VSL#3 (d 8-14 p); (B) Clindamycin + VSL#3 for 7 days (d 1-7 a + p); (C) no therapy
group for 7 days (controls). Figure 3D shows the comparison of absolute amounts (in mmol) at the end of each 7 days period.
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probiotics were added after using antibiotics, the SCFA
production increased. Propionate production was
decreased when antibiotics and probiotics were used
together. Enhanced production of lactate was observed
both when probiotics were administrated together with
Clindamycin or when they were administered after
seven days of clindamycin administration.
Production of putrefactive microbial metabolites
Branched chain fatty acids (BCFA; iso-butyrate and iso-
valerate) and ammonia are metabolites produced from
protein fermentation, a process which is generally
believed to be putrefactive and leading to production of
toxic metabolites. These products are deleterious for host
health [22].
Figure 5 presents the cumulative total production of
BCFA. BCFA are produced in small amounts for every
test variation compared to the SCFA (about 20 to 40 fold
lower). Total BCFA production was highest when probio-
tic was administered after clindamycin. However, when
Clindamycin and probiotics were administered at the
same time, the BCFA production was decreased. In the
experiments in which Clindamycin was administered (the
first 7 days), the BCFA production was comparable to the
control. Therefore the decreasing effect probably was
induced by the use of probiotics. When probiotics were
administered after a week treatment with Clindamycin,
this decreasing effect in BCFA production was not
observed.
Figure 6 shows the cumulative total production of
ammonia. For ammonia the production was decreased
between day 3 and 7 in the test experiments compared
to the control. In the experiments in which Clindamycin
was administered, as well as in which Clindamycin was
administered together with probiotics, the ammonia
production was reduced just as observed for the BCFA.
Composition of the microbiota
To determine the effects of Clindamycin and the pro-
biotics on the composition of the microbiota, the I-chip
platform was used. The I-chip contained roughly 400
probes, some for group-level detection (e.g Bifidobacter-
ium genus) and some for the detection of individual
species (e.g. Bifidobacterium longum). Some groups and
species were covered by more than one probe. In all
cases the hybridization to these multiple probes corre-
lated very well. However, not al probes gave a signal
above background noise, which was expected, as not all
microorganisms are present above the level of detection
of the method (approximately 107 CFU/g). Due to the
different nature of each probe (different sequence),
hybridization intensity does not necessarily reflect abun-
dance. Difference in GC-content results in different
hybridization efficiencies. Although the I-Chip at most
Figure 4 Cumulative production of lactate (D- and L-lactate) during the different experiments in TIM-2: (A) Clindamycin for 7 days (d
1-7 a) followed by VSL#3 (d 8-14 p); (B) Clindamycin + VSL#3 for 7 days (d 1-7 a + p); (C) no therapy group for 7 days (controls).
Figure 4D shows the comparison of absolute amounts (in mmol) at the end of each 7 days period.
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is semi-quantitative, comparing signals from one and the
same hybridization does allow interpretation of the
increase or decrease of certain probes. For the TIM-2
experiments samples from time points 0, 7 and 14 were
analyzed.
Figure 7 shows the results of the I-chip analysis. Dis-
played is the fold-increase in signal between the start
and the end of the fermentation period compared to the
control. For day 14 of the experiment with Clindamycin
followed by probiotics the results at day 14 were com-
pared with the same experiment at day 7, after Clinda-
mycin only.
Different shades of green reflect more than 2, more
than 3 and more than 4 times increases of microbial
species, genera or groups compared to the control,
while the different shades of red reflect the more than 2,
3 and 4 times decrease of microbial species, genera or
groups compared to the control.
Comparing the experiments receiving Clindamycin to
the control experiment, the experiments with administra-
tion of Clindamycin showed a decrease in Bifidobacerium
animalis Bifidobacterium longum, Crenarchaeota, Entero-
bacteriaceae, Lactococcus lactis subsp. cremoris, Lactococ-
cus lactis subsp. and an increase in Bifidobacterium
Figure 5 Cumulative production for the branched chain fatty acids (BCFA) iso-butyrate and iso-valerate during the different experiments in
TIM-2: (A) Clindamycin for 7 days (d 1-7 a) followed by VSL#3 (d 8-14 p); (B) Clindamycin + VSL#3 for 7 days (d 1-7 a + p); (C) no therapy
group for 7 days (controls). Figure 5D shows the comparison of absolute amounts (in mmol) at the end of each 7 days period.
Figure 6 Cumulative production for ammonia during the different experiments in TIM-2 (A) (Clindamycin for 7 days (d 1-7 a) followed
by VSL#3 (d 8-14 p); Clindamycin + VSL#3 for 7 days (d 1-7 a + p); no therapy group for 7 days (controls). Figure 6B shows the
comparison of absolute amounts (in mmol) at the end of each 7 days period.
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bifidum Eubacterium eligens, Bacteroidetes, Bactetroi-
dales, Ruminococcus albus, Ruminococcus bromii and
Fusobacterium prausnitzii.
When Clindamycin and probiotics were administered
together the following species increased compared to the
control: Bifidobacterium animalis, Enterobacter cloaca/
Serratia marcesens/Salmonella typhi, Enterococcus spe-
cies, Haloanaerobiale, Lactobacillus acidophilus, Lactoba-
cillaceae, Lactobacillus casei and paracasei, Lactobacillus
gasseri, Lactobacillus sakei, Microbacteriaceae, Nitros-
pirae, Parabasilidea peptostreptococcus asaccharolyticum,
Streptococcus groups and Streptococcus salivarius.
Bifidobacterium longum (which was in the probiotic mix-
ture) decreased less strong than when Clindamycin was
administered alone.
When Clindamycin was administered for 7 days and
the probiotics were administered the week thereafter the
bacteria that increased compared to the situation after
antibiotic treatment alone were Bifidobacterium adoles-
centis/Bifidobacterium angulatum, Bifidobactrium
longum, Collinsella aerofaciens, Enterococcus hirae,
Eubacterium siraeum, Eubacterium xylanophilum, Eur-
yachaeota, Moraxellaceae and Peptostreptococcus micros.
The groups that decreased were Bifidobacterium catenu-
latum, Bifidobacteriaceae, Brevibacteriaceae, Campylo-
bacter coli/jejuni, Clostridium coccoides/Ruminococcus
productus, Clostridium sporogenes, Enterobacter cloacae/
Serratia marcesens, Salmonella typhi/Klebsiella penumo-
niae, Eubacterium contortum, Haloanaerobiales, Lacto-
bacillus acidophilus, Lactobacillus casei and paracasei
and Phascolarcobacterium faecium.
Administration of clindamycin together with probiotics
has positive effect on lactobacilli while the administration
of probiotic after antibiotic has negative effect on same
bacterial group. For the bifidobacteria this seemed to be
divided in two groups, increase in one group (namely
Figure 7 Graphic representation of the I-chip results showing those probes that i) give a signal above the background, and ii)
differed by a factor of > 2 from the control for the first two columns. For the third column the effect of the addition of probiotics after
treatment with Clindamycin was compared to the result after treatment with Clindamycin alone (middle column). Green signifies a factor of 2 or
higher compared to the control (or antibiotic experiment at day 7) and red stands for a factor of 2 or more lower compared to the control (or
antibiotic at day 7).
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Bifidobacterium animalis) was observed when Clindamy-
cin together with probiotics, but not when probiotic was
administated after Clindamycin. Decrease in another
group (namely Bifidobacterium catenulatum) was
observed only when probiotics were administrated after
clindamycin but not in other experimental setups
Statistical analyses (SAM) of the data obtained with the
I-chip showed that all time point 0 samples clustered
together (data not shown) and thus could be considered
equal. The SAM analysis did not add new information to
the other analysis performed on the I-chip data.
According to the I-chip results not all strains from the
probiotic mixture increased when the mix was added to
the TIM-2 system; therefore we plated the mixture to get
an idea of the amount and proportions of the bacterial
strains in the mixture. The amount of bifidobacteria was
very low in the mixture and only Bifidobacterium longum
could be identified.
After administration of clindamycin, a decrease in bifido-
bacteria and lactococci groups was observed, whereas in
the experiment in which Clindamycin was administered
together with the probiotic mix, an increase in Bifidobac-
terium animalis as well as several Lactobacillus strains
could be observed, and decrease of Bifidobacterium longum
was also less strong, decreasing from 4 fold to 2 fold.
Increase in the beneficial bacterial group Lactobacilli
was observed when Clindamycin and probiotics were
administered together, while if the probiotics were admi-
nistered following the administration of Clindamycin the
level of lactobacilli was lower. In summary, in this study
we could demonstrate that the simultaneous administra-
tion of anti- and probiotics had the most significant posi-
tive effects on intestinal homeostasis by stabilizing the
intestinal microbial composition, increased production of
short chain fatty acids and decreasing the production of
toxic microbial metabolites like ammonia and other
branched chain fatty acids. We could also show that pro-
biotics are active when applied simultaneous with anti-
biotics. Therefore the administration of probiotics could
be of significant advantage in the prevention of AAD and
CDI by surveillance of intestinal metabolic balance.
Conclusions
Administration of VSL#3 parallel with the clindamycin
therapy had a beneficial and stabilizing effect on the intest-
inal metabolic homeostasis by decreasing toxic metabolites
and protecting the endogenic microbiota from destruction.
Probiotics could be a reasonable strategy in prevention of
antibiotic associated disturbances of the intestinal home-
ostasis and disorders.
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